- Home
- VLGEA vs GOSS Comparison
VLGEA vs GOSS Comparison
Compare VLGEA & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLGEA
- GOSS
- Stock Information
- Founded
- VLGEA 1937
- GOSS 2015
- Country
- VLGEA United States
- GOSS United States
- Employees
- VLGEA N/A
- GOSS N/A
- Industry
- VLGEA Food Chains
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- VLGEA Consumer Staples
- GOSS Health Care
- Exchange
- VLGEA Nasdaq
- GOSS Nasdaq
- Market Cap
- VLGEA 480.8M
- GOSS 501.2M
- IPO Year
- VLGEA N/A
- GOSS 2019
- Fundamental
- Price
- VLGEA $33.07
- GOSS $2.37
- Analyst Decision
- VLGEA
- GOSS Strong Buy
- Analyst Count
- VLGEA 0
- GOSS 6
- Target Price
- VLGEA N/A
- GOSS $8.60
- AVG Volume (30 Days)
- VLGEA 53.1K
- GOSS 3.0M
- Earning Date
- VLGEA 12-02-2025
- GOSS 11-05-2025
- Dividend Yield
- VLGEA 3.10%
- GOSS N/A
- EPS Growth
- VLGEA 12.16
- GOSS N/A
- EPS
- VLGEA 3.81
- GOSS N/A
- Revenue
- VLGEA $2,320,690,000.00
- GOSS $40,237,000.00
- Revenue This Year
- VLGEA N/A
- GOSS N/A
- Revenue Next Year
- VLGEA N/A
- GOSS $16.11
- P/E Ratio
- VLGEA $8.68
- GOSS N/A
- Revenue Growth
- VLGEA 3.76
- GOSS N/A
- 52 Week Low
- VLGEA $28.79
- GOSS $0.66
- 52 Week High
- VLGEA $40.15
- GOSS $3.60
- Technical
- Relative Strength Index (RSI)
- VLGEA 49.28
- GOSS 48.07
- Support Level
- VLGEA $30.90
- GOSS $2.28
- Resistance Level
- VLGEA $33.43
- GOSS $2.52
- Average True Range (ATR)
- VLGEA 0.87
- GOSS 0.15
- MACD
- VLGEA 0.19
- GOSS 0.02
- Stochastic Oscillator
- VLGEA 85.80
- GOSS 62.79
About VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.